A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or Ocular Hypertension in India

Trial Profile

A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or Ocular Hypertension in India

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Tafluprost (Primary) ; Timolol (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 30 Jun 2016 New source identified and integrated Clinicaltrials.gov (NCT01254604)
    • 30 Jun 2016 New trial record
    • 13 Jun 2016 Primary endpoint has been met. (Mean Diurnal IOP Change From Baseline at Week 4 - Study Eye), as per an article published in the International Journal of Clinical Practice.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top